Expression of interleukin-31 in hypertrophic scar from postoperative incision tissue
10.3760/cma.j.issn.1671-0290.2023.04.005
- VernacularTitle:白细胞介素-31在外科术后切口增生性瘢痕中的表达
- Author:
Huizi SONG
1
;
Hongsen BI
;
Bailin PAN
;
Chen ZHANG
;
Jing SU
;
Zelian QIN
Author Information
1. 北京大学第三医院成形外科，北京 100191
- Keywords:
Cicatrix, hypertrophic;
Interleukin-31;
Myofibroblast;
Inflammation;
Itch
- From:
Chinese Journal of Medical Aesthetics and Cosmetology
2023;29(4):272-275
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the interleukin-31 protein expression in the hypertrophic scar of incision tissue after surgery and its underlying pathological impact.Methods:From February 2022 to February 2023, three HS patients scar tissue (HS) and their normal skin tissue (Control, NS) were obtained. Two patients were female and one patient was male. The tissues were fixed in 4% formalin and embedded in paraffin. Haematoxylin-eosin (HE) stain and immunohistochemical stain were used to evaluate the epidermal thickness, myofibroblasts of dermis and the expression level of IL-31 between HS and NS.Results:The epidermis thickness was (303.88±46.03) μm in HS group, while (133.02±17.40) μm in NS group ( t=12.60, P<0.001). The expression level of IL-31 protein was measured by IRS score and positive cell density. The IRS score was 9.89±2.03 of the basal layer in HS group and was 4.33±1.66 of the basal layer in NS group. The positive cell density was 786 343.83±159 627.97 of the basal layer in HS group ( P<0.001) and was 555 457.61±128 097.21 of the basal layer in NS group ( P=0.014). In the dermis layer, the IRS score was 7.11±1.05 in HS group and was 4.33±0.71 in NS group, the positive cell density was 156 760.97±26 046.10 in HS group ( P<0.001) and was 49 576.01±52 369.33 in NS group ( P<0.001). In the dermis layer, the count of myofibroblasts was 120.44±15.75 in HS group while was 27.39±14.89 in NS group ( t=23.79, P<0.001). Conclusions:Our study demonstrates that both myofibroblast count and IL-31 protein expression level are notably increased in HS patients. The expression of IL-31 protein is prominent in the cytoplasm of myofibroblasts, basal cells, macrophages and mast cells which could implicate that IL-31 may be a potential therapeutic target to enhance the resolution of HS.
